Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-12

AUTHORS

Godfrey M Mubyazi, Miguel A Gonzalez-Block

ABSTRACT

INTRODUCTION: Research is an essential tool in facing the challenges of scaling up interventions and improving access to services. As in many other countries, the translation of research evidence into drug policy action in Tanzania is often constrained by poor communication between researchers and policy decision-makers, individual perceptions or attitudes towards the drug and hesitation by some policy decision-makers to approve change when they anticipate possible undesirable repercussions should the policy change as proposed. Internationally, literature on the role of researchers on national antimalarial drug policy change is limited. OBJECTIVES: To describe the (a) role of researchers in producing evidence that influenced the Tanzanian government replace chloroquine (CQ) with sulfadoxine-pyrimethamine (SP) as the first-line drug and the challenges faced in convincing policy-makers, general practitioners, pharmaceutical industry and the general public on the need for change (b) challenges ahead before a new drug combination treatment policy is introduced in Tanzania. METHODS: In-depth interviews were held with national-level policy-makers, malaria control programme managers, pharmaceutical officers, general medical practitioners, medical research library and publications officers, university academicians, heads of medical research institutions and district and regional medical officers. Additional data were obtained through a review of malaria drug policy documents and participant observations were also done. RESULTS: In year 2001, the Tanzanian Government officially changed its malaria treatment policy guidelines whereby CQ--the first-line drug for a long time was replaced with SP. This policy decision was supported by research evidence indicating parasite resistance to CQ and clinical CQ treatment failure rates to have reached intolerable levels as compared to SP and amodiaquine (AQ). Research also indicated that since SP was also facing rising resistance trend, the need for a more effective drug was indispensable but for an interim 5-10 year period it was justifiable to recommend SP that was relatively more cost-effective than CQ and AQ. The government launched the policy change considering that studies (ethically approved by the Ministry of Health) on therapeutic efficacy and cost-effectiveness of artemisinin drug combination therapies were underway. Nevertheless, the process of communicating research results and recommendations to policy-making authorities involved critical debates between policy makers and researchers, among the researchers themselves and between the researchers and general practitioners, the speculative media reports on SP side-effects and reservations by the general public concerning the rationale for policy change, when to change, and to which drug of choice. CONCLUSION: Changing national drug policy will remain a sensitive issue that cannot be done overnight. However, to ensure that research findings are recognised and the recommendations emanating from such findings are effectively utilized, a systematic involvement of all the key stakeholders (including policy-makers, drug manufacturers, media, practitioners and the general public) at all stages of research is crucial. It also matters how and when research information is communicated to the stakeholders. Professional organizations such as the East African Network on Malaria Treatment have potential to bring together malaria researchers, policy-makers and other stakeholders in the research-to-drug policy change interface. More... »

PAGES

51

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2875-4-51

DOI

http://dx.doi.org/10.1186/1475-2875-4-51

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034734271

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16242017


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1605", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Policy and Administration", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/16", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Studies in Human Society", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimalarials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chloroquine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Policy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Malaria, Falciparum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasmodium falciparum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimethamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfadoxine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tanzania", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "World Health Organization", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Institute for Medical Research", 
          "id": "https://www.grid.ac/institutes/grid.416716.3", 
          "name": [
            "National Institute For Medical Research (NIMR), Department of Health Systems and Policy Research, Centre for Enhancement of Effective Malaria Interventions (CEEMI), P.O Box 9653, Dar es Salaam, United Republic of Tanzania"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mubyazi", 
        "givenName": "Godfrey M", 
        "id": "sg:person.0667054214.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667054214.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alliance for Health Policy and Systems Research", 
          "id": "https://www.grid.ac/institutes/grid.458360.c", 
          "name": [
            "Alliance For Health Policy and Systems Research (AHPSR), World Health Organization, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonzalez-Block", 
        "givenName": "Miguel A", 
        "id": "sg:person.0665322220.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665322220.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1046/j.1365-3156.2001.00799.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008532530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-3156.2001.00679.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010465379"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06344-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010894122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(99)90375-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015232649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0035-9203(57)90039-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033518531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0035-9203(01)90207-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033697465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1377/hlthaff.21.3.166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039882575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1478-4505-1-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052367250", 
          "https://doi.org/10.1186/1478-4505-1-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0035-9203(96)90129-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053030109"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074763507", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074763517", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075498998", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4269/ajtmh.2004.71.2_suppl.0700001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076883960"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-12", 
    "datePublishedReg": "2005-12-01", 
    "description": "INTRODUCTION: Research is an essential tool in facing the challenges of scaling up interventions and improving access to services. As in many other countries, the translation of research evidence into drug policy action in Tanzania is often constrained by poor communication between researchers and policy decision-makers, individual perceptions or attitudes towards the drug and hesitation by some policy decision-makers to approve change when they anticipate possible undesirable repercussions should the policy change as proposed. Internationally, literature on the role of researchers on national antimalarial drug policy change is limited.\nOBJECTIVES: To describe the (a) role of researchers in producing evidence that influenced the Tanzanian government replace chloroquine (CQ) with sulfadoxine-pyrimethamine (SP) as the first-line drug and the challenges faced in convincing policy-makers, general practitioners, pharmaceutical industry and the general public on the need for change (b) challenges ahead before a new drug combination treatment policy is introduced in Tanzania.\nMETHODS: In-depth interviews were held with national-level policy-makers, malaria control programme managers, pharmaceutical officers, general medical practitioners, medical research library and publications officers, university academicians, heads of medical research institutions and district and regional medical officers. Additional data were obtained through a review of malaria drug policy documents and participant observations were also done.\nRESULTS: In year 2001, the Tanzanian Government officially changed its malaria treatment policy guidelines whereby CQ--the first-line drug for a long time was replaced with SP. This policy decision was supported by research evidence indicating parasite resistance to CQ and clinical CQ treatment failure rates to have reached intolerable levels as compared to SP and amodiaquine (AQ). Research also indicated that since SP was also facing rising resistance trend, the need for a more effective drug was indispensable but for an interim 5-10 year period it was justifiable to recommend SP that was relatively more cost-effective than CQ and AQ. The government launched the policy change considering that studies (ethically approved by the Ministry of Health) on therapeutic efficacy and cost-effectiveness of artemisinin drug combination therapies were underway. Nevertheless, the process of communicating research results and recommendations to policy-making authorities involved critical debates between policy makers and researchers, among the researchers themselves and between the researchers and general practitioners, the speculative media reports on SP side-effects and reservations by the general public concerning the rationale for policy change, when to change, and to which drug of choice.\nCONCLUSION: Changing national drug policy will remain a sensitive issue that cannot be done overnight. However, to ensure that research findings are recognised and the recommendations emanating from such findings are effectively utilized, a systematic involvement of all the key stakeholders (including policy-makers, drug manufacturers, media, practitioners and the general public) at all stages of research is crucial. It also matters how and when research information is communicated to the stakeholders. Professional organizations such as the East African Network on Malaria Treatment have potential to bring together malaria researchers, policy-makers and other stakeholders in the research-to-drug policy change interface.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1475-2875-4-51", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1030597", 
        "issn": [
          "1475-2875"
        ], 
        "name": "Malaria Journal", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug", 
    "pagination": "51", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a575c909973ec14036ac1bec8f96953deae457fe492faef9a853bfdcd9c9b063"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16242017"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101139802"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2875-4-51"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034734271"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2875-4-51", 
      "https://app.dimensions.ai/details/publication/pub.1034734271"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000550.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1475-2875-4-51"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-4-51'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-4-51'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-4-51'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-4-51'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      21 PREDICATES      56 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2875-4-51 schema:about N16ecdf7c23784ae09f88dd0403b489af
2 N286a49ab521945e59ef709d019d22387
3 N3e8649700a504b2bb3f5b49818c74cc1
4 N617480e6f03845a9b341abcb500e1ee1
5 N63555f0f0fea4cecb3c84c3cc5224dc8
6 N64bed6bbc24646069c8774f60331fd02
7 N67ed64d2ac3b4c42931116ce99c36322
8 N6c200e87958e4f8a8743bb4fceb7e254
9 Nb84cd08392d04b1a9dc0d0643b092363
10 Nc2b100e84f2349ad8df27ed53473958c
11 Ndd04816b23014d4c8929c6940cb44aa6
12 Ne277ae2f283d44da99c72d2b02634bfc
13 Ne393807283234a07b506604daf34be5d
14 Ne5afc15cb3774991a1f0675dac10cd5a
15 anzsrc-for:16
16 anzsrc-for:1605
17 schema:author N1da3b671d7e846c6b5dde29784cbb555
18 schema:citation sg:pub.10.1186/1478-4505-1-2
19 https://app.dimensions.ai/details/publication/pub.1074763507
20 https://app.dimensions.ai/details/publication/pub.1074763517
21 https://app.dimensions.ai/details/publication/pub.1075498998
22 https://doi.org/10.1016/0035-9203(57)90039-1
23 https://doi.org/10.1016/s0035-9203(01)90207-x
24 https://doi.org/10.1016/s0035-9203(96)90129-7
25 https://doi.org/10.1016/s0140-6736(01)06344-9
26 https://doi.org/10.1016/s0140-6736(99)90375-6
27 https://doi.org/10.1046/j.1365-3156.2001.00679.x
28 https://doi.org/10.1046/j.1365-3156.2001.00799.x
29 https://doi.org/10.1377/hlthaff.21.3.166
30 https://doi.org/10.4269/ajtmh.2004.71.2_suppl.0700001
31 schema:datePublished 2005-12
32 schema:datePublishedReg 2005-12-01
33 schema:description INTRODUCTION: Research is an essential tool in facing the challenges of scaling up interventions and improving access to services. As in many other countries, the translation of research evidence into drug policy action in Tanzania is often constrained by poor communication between researchers and policy decision-makers, individual perceptions or attitudes towards the drug and hesitation by some policy decision-makers to approve change when they anticipate possible undesirable repercussions should the policy change as proposed. Internationally, literature on the role of researchers on national antimalarial drug policy change is limited. OBJECTIVES: To describe the (a) role of researchers in producing evidence that influenced the Tanzanian government replace chloroquine (CQ) with sulfadoxine-pyrimethamine (SP) as the first-line drug and the challenges faced in convincing policy-makers, general practitioners, pharmaceutical industry and the general public on the need for change (b) challenges ahead before a new drug combination treatment policy is introduced in Tanzania. METHODS: In-depth interviews were held with national-level policy-makers, malaria control programme managers, pharmaceutical officers, general medical practitioners, medical research library and publications officers, university academicians, heads of medical research institutions and district and regional medical officers. Additional data were obtained through a review of malaria drug policy documents and participant observations were also done. RESULTS: In year 2001, the Tanzanian Government officially changed its malaria treatment policy guidelines whereby CQ--the first-line drug for a long time was replaced with SP. This policy decision was supported by research evidence indicating parasite resistance to CQ and clinical CQ treatment failure rates to have reached intolerable levels as compared to SP and amodiaquine (AQ). Research also indicated that since SP was also facing rising resistance trend, the need for a more effective drug was indispensable but for an interim 5-10 year period it was justifiable to recommend SP that was relatively more cost-effective than CQ and AQ. The government launched the policy change considering that studies (ethically approved by the Ministry of Health) on therapeutic efficacy and cost-effectiveness of artemisinin drug combination therapies were underway. Nevertheless, the process of communicating research results and recommendations to policy-making authorities involved critical debates between policy makers and researchers, among the researchers themselves and between the researchers and general practitioners, the speculative media reports on SP side-effects and reservations by the general public concerning the rationale for policy change, when to change, and to which drug of choice. CONCLUSION: Changing national drug policy will remain a sensitive issue that cannot be done overnight. However, to ensure that research findings are recognised and the recommendations emanating from such findings are effectively utilized, a systematic involvement of all the key stakeholders (including policy-makers, drug manufacturers, media, practitioners and the general public) at all stages of research is crucial. It also matters how and when research information is communicated to the stakeholders. Professional organizations such as the East African Network on Malaria Treatment have potential to bring together malaria researchers, policy-makers and other stakeholders in the research-to-drug policy change interface.
34 schema:genre research_article
35 schema:inLanguage en
36 schema:isAccessibleForFree true
37 schema:isPartOf N2b8a967e92654da3b38b82bfa024433b
38 N53843eedfb36407aa62e9e1586b91369
39 sg:journal.1030597
40 schema:name Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug
41 schema:pagination 51
42 schema:productId N0d4c2f780e5642fe9b2c677366aae44c
43 N59b0c14a9ccb447c93c8f8a801d17049
44 N7addf69b6f3a4929a411be411785ac33
45 Nc366a1633475435ab00a5f8e9d35effb
46 Nd97f9eb7b96441f5aea7e1fc9e6a17af
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034734271
48 https://doi.org/10.1186/1475-2875-4-51
49 schema:sdDatePublished 2019-04-10T18:26
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher Nbb91096e7f174177a0243b727a84f2ee
52 schema:url http://link.springer.com/10.1186%2F1475-2875-4-51
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N0d4c2f780e5642fe9b2c677366aae44c schema:name pubmed_id
57 schema:value 16242017
58 rdf:type schema:PropertyValue
59 N16ecdf7c23784ae09f88dd0403b489af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Plasmodium falciparum
61 rdf:type schema:DefinedTerm
62 N1da3b671d7e846c6b5dde29784cbb555 rdf:first sg:person.0667054214.85
63 rdf:rest Ne51479d99d0a4aa28b0cb58f084b7663
64 N286a49ab521945e59ef709d019d22387 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Animals
66 rdf:type schema:DefinedTerm
67 N2b8a967e92654da3b38b82bfa024433b schema:volumeNumber 4
68 rdf:type schema:PublicationVolume
69 N3e8649700a504b2bb3f5b49818c74cc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Sulfadoxine
71 rdf:type schema:DefinedTerm
72 N53843eedfb36407aa62e9e1586b91369 schema:issueNumber 1
73 rdf:type schema:PublicationIssue
74 N59b0c14a9ccb447c93c8f8a801d17049 schema:name dimensions_id
75 schema:value pub.1034734271
76 rdf:type schema:PropertyValue
77 N617480e6f03845a9b341abcb500e1ee1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N63555f0f0fea4cecb3c84c3cc5224dc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Chloroquine
82 rdf:type schema:DefinedTerm
83 N64bed6bbc24646069c8774f60331fd02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Pyrimethamine
85 rdf:type schema:DefinedTerm
86 N67ed64d2ac3b4c42931116ce99c36322 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Drug Resistance
88 rdf:type schema:DefinedTerm
89 N6c200e87958e4f8a8743bb4fceb7e254 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Research
91 rdf:type schema:DefinedTerm
92 N7addf69b6f3a4929a411be411785ac33 schema:name readcube_id
93 schema:value a575c909973ec14036ac1bec8f96953deae457fe492faef9a853bfdcd9c9b063
94 rdf:type schema:PropertyValue
95 Nb84cd08392d04b1a9dc0d0643b092363 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Tanzania
97 rdf:type schema:DefinedTerm
98 Nbb91096e7f174177a0243b727a84f2ee schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 Nc2b100e84f2349ad8df27ed53473958c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Health Policy
102 rdf:type schema:DefinedTerm
103 Nc366a1633475435ab00a5f8e9d35effb schema:name doi
104 schema:value 10.1186/1475-2875-4-51
105 rdf:type schema:PropertyValue
106 Nd97f9eb7b96441f5aea7e1fc9e6a17af schema:name nlm_unique_id
107 schema:value 101139802
108 rdf:type schema:PropertyValue
109 Ndd04816b23014d4c8929c6940cb44aa6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Malaria, Falciparum
111 rdf:type schema:DefinedTerm
112 Ne277ae2f283d44da99c72d2b02634bfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name World Health Organization
114 rdf:type schema:DefinedTerm
115 Ne393807283234a07b506604daf34be5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Drug Combinations
117 rdf:type schema:DefinedTerm
118 Ne51479d99d0a4aa28b0cb58f084b7663 rdf:first sg:person.0665322220.38
119 rdf:rest rdf:nil
120 Ne5afc15cb3774991a1f0675dac10cd5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Antimalarials
122 rdf:type schema:DefinedTerm
123 anzsrc-for:16 schema:inDefinedTermSet anzsrc-for:
124 schema:name Studies in Human Society
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1605 schema:inDefinedTermSet anzsrc-for:
127 schema:name Policy and Administration
128 rdf:type schema:DefinedTerm
129 sg:journal.1030597 schema:issn 1475-2875
130 schema:name Malaria Journal
131 rdf:type schema:Periodical
132 sg:person.0665322220.38 schema:affiliation https://www.grid.ac/institutes/grid.458360.c
133 schema:familyName Gonzalez-Block
134 schema:givenName Miguel A
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665322220.38
136 rdf:type schema:Person
137 sg:person.0667054214.85 schema:affiliation https://www.grid.ac/institutes/grid.416716.3
138 schema:familyName Mubyazi
139 schema:givenName Godfrey M
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667054214.85
141 rdf:type schema:Person
142 sg:pub.10.1186/1478-4505-1-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052367250
143 https://doi.org/10.1186/1478-4505-1-2
144 rdf:type schema:CreativeWork
145 https://app.dimensions.ai/details/publication/pub.1074763507 schema:CreativeWork
146 https://app.dimensions.ai/details/publication/pub.1074763517 schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1075498998 schema:CreativeWork
148 https://doi.org/10.1016/0035-9203(57)90039-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033518531
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s0035-9203(01)90207-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033697465
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/s0035-9203(96)90129-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053030109
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0140-6736(01)06344-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010894122
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/s0140-6736(99)90375-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015232649
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1046/j.1365-3156.2001.00679.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010465379
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1046/j.1365-3156.2001.00799.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008532530
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1377/hlthaff.21.3.166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039882575
163 rdf:type schema:CreativeWork
164 https://doi.org/10.4269/ajtmh.2004.71.2_suppl.0700001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076883960
165 rdf:type schema:CreativeWork
166 https://www.grid.ac/institutes/grid.416716.3 schema:alternateName National Institute for Medical Research
167 schema:name National Institute For Medical Research (NIMR), Department of Health Systems and Policy Research, Centre for Enhancement of Effective Malaria Interventions (CEEMI), P.O Box 9653, Dar es Salaam, United Republic of Tanzania
168 rdf:type schema:Organization
169 https://www.grid.ac/institutes/grid.458360.c schema:alternateName Alliance for Health Policy and Systems Research
170 schema:name Alliance For Health Policy and Systems Research (AHPSR), World Health Organization, Geneva, Switzerland
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...